Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical OfficerPRNewsWire • 10/06/21
Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.GlobeNewsWire • 09/27/21
Rafael Holdings Continues to Expand its Management Team with a Highly Experienced Global Biopharmaceutical Executive to Build a Fully Integrated Cancer Metabolism Therapeutics Company and Announces Inducement Grant Under NYSE Rule 303A.08PRNewsWire • 09/24/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Rafael Holdings, Inc. with Rafael Pharmaceuticals, Inc.Newsfile Corp • 08/26/21
President and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021GlobeNewsWire • 08/26/21
Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract CancerGlobeNewsWire • 08/25/21
Rafael Holdings Expands Leadership Team with Three Highly Experienced Global Biopharmaceutical Executives to Build a Fully Integrated Cancer Metabolism Therapeutics CompanyPRNewsWire • 08/17/21
RAFAEL (RFL) STOCKHOLDER ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Rafael Holdings, Inc.Business Wire • 08/16/21
Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)GlobeNewsWire • 07/01/21
Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) CongressGlobeNewsWire • 06/30/21
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary CancerGlobeNewsWire • 06/29/21
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Rafael Holdings, Inc. and Encourages Stockholders to Contact the Firm - RFLNewsfile Corp • 06/28/21
RAFAEL HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Rafael Holdings, Inc. - RFLBusiness Wire • 06/24/21
Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021PRNewsWire • 06/23/21
Rafael Holdings Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Rafael Holdings, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – RFLBusiness Wire • 06/21/21
Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology CompanyPRNewsWire • 06/21/21
Rafael Holdings Appoints Three Highly Experienced Biopharmaceutical Leaders to its Board of DirectorsPRNewsWire • 06/14/21
Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific ProgramGlobeNewsWire • 05/26/21
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)GlobeNewsWire • 03/30/21
